Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Equity Average (2020 - 2023)

Cullinan Therapeutics has reported Equity Average over the past 4 years, most recently at $484.2 million for Q3 2023.

  • Quarterly results put Equity Average at $484.2 million for Q3 2023, down 18.67% from a year ago — trailing twelve months through Sep 2023 was $484.2 million (down 18.67% YoY), and the annual figure for FY2022 was $480.2 million, up 53.5%.
  • Equity Average for Q3 2023 was $484.2 million at Cullinan Therapeutics, down from $492.6 million in the prior quarter.
  • Over the last five years, Equity Average for CGEM hit a ceiling of $595.4 million in Q3 2022 and a floor of $94.2 million in Q3 2020.
  • Median Equity Average over the past 4 years was $458.1 million (2021), compared with a mean of $400.4 million.
  • Biggest five-year swings in Equity Average: surged 379.76% in 2021 and later fell 18.67% in 2023.
  • Cullinan Therapeutics' Equity Average stood at $144.9 million in 2020, then soared by 200.47% to $435.4 million in 2021, then increased by 28.74% to $560.6 million in 2022, then decreased by 13.63% to $484.2 million in 2023.
  • The last three reported values for Equity Average were $484.2 million (Q3 2023), $492.6 million (Q2 2023), and $510.3 million (Q1 2023) per Business Quant data.